Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials
Servicios
Servicios
Fecha de publicación
2014Título de revista
Arthritis and Rheumatology
Tipo de contenido
Publicación de congreso
